β³ Fetching live dividend data...
Home βΊ Calculator βΊ MNK Dividend Calculator 2026
Mallinckrodt plc Β· AMEX
Price: $0.34 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
MNK is not a dividend-focused stock
MNK pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Mallinckrodt plc (MNK) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Mallinckrodt plc operates as a global pharmaceutical company, engaged in the development, manufacturing, marketing, and distribution of specialized medical products and therapies. Its extensive reach covers the United States, Europe, the Middle East, Africa, and various other international markets. The firm's business operations are segmented into two core divisions: Specialty Brands and Specialty Generics. Under its Specialty Brands arm, Mallinckrodt offers a range of pharmaceuticals for autoimmune and rare diseases, spanning therapeutic areas such as neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. The branded portfolio also encompasses immunotherapy solutions, critical care treatments for neonatal respiratory conditions, pain management drugs, cultured skin substitutes, and gastrointestinal remedies. Key branded products include Acthar Gel, a corticotropin injection prescribed for conditions like rheumatoid arthritis, infantile spasms, and multiple sclerosis; INOmax, a vasodilator used to enhance oxygenation and lessen the need for extracorporeal membrane oxygenation; the Therakos photopheresis platform for immunotherapy; Amitiza, a treatment for constipation; and StrataGraft, designed for adults with deep partial-thickness burns. In its development pipeline, Mallinckrodt is advancing Terlipressin for hepatorenal syndrome and SLN 501, a ribonucleic acid silencing therapeutic. Additionally, through its Specialty Generics segment, the company supplies specialized generic medications and active pharmaceutical ingredients (APIs). Mallinckrodt's branded offerings are marketed to a diverse array of healthcare professionals and institutions, including physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company has also forged a strategic collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference (RNAi) drug targets. Established in 1867, Mallinckrodt plc maintains its headquarters in Dublin, Ireland.
No. Mallinckrodt plc (MNK) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. MNK has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open MNK position with:
Real after-tax yield depends on where you live and how you hold MNK.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
MNK pays quarterly β 4 times per year. Ex-div: β.
How MNK compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MNK sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-10-14 | 137,000 | $90.00 | $12.33M | ||
| Buy | 2026-09-24 | 463,000 | $91.00 | $42.13M | ||
| Buy | 2023-12-05 | 75,000 | $37.50 | $2.81M | ||
| J-Other | 2023-11-14 | 1,093,857 | β | β | ||
| J-Other | 2023-11-14 | 2,033,257 | β | β | ||
| D-Return | 2023-11-14 | 32,000 | β | β | ||
| D-Return | 2023-11-14 | 189,863 | β | β | ||
| D-Return | 2023-11-14 | 672,948 | β | β | ||
| D-Return | 2023-11-14 | 62,288 | β | β | ||
| D-Return | 2023-11-14 | 96,660 | β | β |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Compare MNK with peers: MNK vs APTO Β· MNK vs BVXV Β· MNK vs GMDA
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Insiders are net buyers β historically a positive signal for dividend sustainability. Last purchase: 2026-10-14
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MNK dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Mallinckrodt plc (MNK) is currently trading at $0.34, 98% below its 52-week high. It does not currently pay a regular dividend.
Mallinckrodt plc (MNK) is a healthcare stock trading at $0.34. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever